gmppb encodes a cytosolic nucleotidyltransferase that produces GDP-mannose from mannose-1-phosphate and GTP (the canonical mannose-1-phosphate guanylyltransferase reaction, EC 2.7.7.13), releasing pyrophosphate.

"Gmppb encodes a cytosolic nucleotidyltransferase that catalyzes formation of **GDP-mannose** from **mannose-1-phosphate** and **GTP** (mannose-1-P + GTP → GDP-mannose + PPi), i.e., the canonical activity of GDP-mannose pyrophosphorylase / mannose-1-phosphate guanylyltransferase (EC 2.7.7.13 as per UniProt context)."

Biochemical assays show the catalytic activity requires Mg2+ and mannose-1-phosphate; omitting either abolishes detectable GDP-mannose formation, establishing substrate and cofactor requirements.

"activity requires **Mg²⁺** and the sugar-phosphate substrate **mannose-1-phosphate**; omitting Mg²⁺ or mannose-1-P yields **no detectable GDP-mannose formation** under the assay conditions."

GMPPB has an N-terminal nucleotidyltransferase/catalytic domain and a C-terminal bacterial transferase hexapeptide-repeat domain forming a left-handed beta-helix, an architecture consistent with its nucleotidyltransferase chemistry.

"GMPPB is described as comprising an **N-terminal nucleotidyltransferase/catalytic domain** and a **C-terminal bacterial transferase hexapeptide-repeat domain** that forms a **left-handed β-helix**; this architecture is reiterated in a 2023 review and aligns with the enzyme’s nucleotidyltransferase chemistry."

GDP-mannose produced by GMPPB is the activated mannose donor used by cytosolic mannosyltransferases and required for dolichol-phosphate-mannose (Dol-P-Man) synthesis, feeding O-mannosylation, N-glycosylation, C-mannosylation, and GPI-anchor formation.

"GDP-mannose is used by cytosolic mannosyltransferases and supports synthesis of **dolichol-phosphate-mannose (Dol-P-Man)**, a required mannose donor for ER mannosylation reactions including **O-mannosylation**, **N-glycosylation**, **C-mannosylation**, and **GPI-anchor formation**."

Impaired GDP-mannose supply reduces O-mannosylation of alpha-dystroglycan, weakening alpha-DG-mediated extracellular matrix interactions and linking GMPPB to dystroglycanopathy.

"impaired GDP-mannose supply reduces α-DG O-mannosylation and thereby weakens α-DG-mediated extracellular matrix interactions."

Wild-type GMPPB is a soluble cytosolic/cytoplasmic enzyme consistent with cytosolic nucleotide-sugar synthesis; several disease-associated missense variants form cytoplasmic aggregates or show altered intracellular distribution.

"Wild-type GMPPB is described as a **soluble cytosolic/cytoplasmic enzyme**, consistent with cytosolic nucleotide-sugar synthesis."

Zebrafish gmppb is broadly/ubiquitously expressed during early embryogenesis (throughout early development by RT-PCR; ubiquitous from 50%-epiboly to 24 hpf), consistent with a housekeeping metabolic role in glycan-precursor supply.

"Whole-mount in situ hybridization indicates **ubiquitous expression** from **50%-epiboly to 24 hpf**, consistent with a housekeeping-like metabolic role in glycan precursor supply during early development."

Zebrafish gmppb morpholino knockdown causes shortened/abnormal CaP motor neuron axons at 24 and 48 hpf, decreased HuC neuronal-marker signal, and reduced larval motor behavior at 2 dpf, supporting a requirement for neuronal differentiation and motor circuit output.

"gmppb knockdown produces abnormal morphology/shortening of motor neuron (CaP) axons observed at **24 and 48 hpf**, decreased neuronal marker signals (e.g., HuC reporter signal), and reduced larval motor behavior measured at **2 dpf**, supporting a requirement for normal neuronal differentiation and motor circuit output."

gmppb morphants show sparse/disordered muscle fibers, increased Evans Blue Dye infiltration (p < 0.001) indicating compromised sarcolemmal integrity, and reduced glycosylated alpha-DG (IIH6 ~71% of wild-type at 48 hpf), placing gmppb upstream of alpha-DG glycosylation rather than as dystroglycan itself.

"an immunoblot readout for the glycosylated α-DG epitope (IIH6 reactivity) in zebrafish shows a reduction to **~71% of wild-type** in gmppb morphants at **48 hpf**, whereas a dystroglycan (dag1) knockdown control shows a stronger reduction (**~15% of wild-type**), supporting a role of gmppb upstream of α-DG glycosylation rather than encoding dystroglycan itself."

In zebrafish knockdown/rescue assays, developmental rescue tracks with catalytic competence: higher-activity human GMPPB variants (e.g., R261C ~50% WT) partially rescue while low-activity variants (e.g., P32L ~10% WT) fail to rescue axon-length phenotypes, supporting an enzyme-activity-driven mechanism.

"variants with higher enzymatic activity rescue neuronal and muscle phenotypes better than low-activity variants: for example, **R261C (~50% of WT activity) partially rescues**, whereas **P32L (~10% of WT activity) fails to rescue** axon-length phenotypes."

A 2024 study reports that ubiquitination regulates GMPPB enzymatic activity: GMPPB interacts with the E3 ligase TRIM67, and reduced GMPPB ubiquitination lowers enzymatic activity without changing GMPPB turnover or its interaction with GMPPA, implying activity (not abundance) is modulated.

"The authors report interaction between GMPPB and the E3 ligase **TRIM67**, and show that reducing GMPPB ubiquitination decreases enzymatic activity without changing GMPPB turnover or its interaction with GMPPA, implying ubiquitination modulates activity rather than abundance."